Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma.
Andrzej BozekBarbara RogalaMartyna MiodonskaGiorgio Walter CanonicaPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2023)
The combination of HDM SCIT and omalizumab is significantly and progressively reducing ICS use and AX in a 24-month study. The combination is significantly more effective than the single treatments or placebo.